We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Synairgen (SNG) ORD GBP 0.01

Sell:3.51p Buy:4.50p 0 Change: 0.25p (5.88%)
Market closed Prices as at close on 11 October 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:3.51p
Buy:4.50p
Change: 0.25p (5.88%)
Market closed Prices as at close on 11 October 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:3.51p
Buy:4.50p
Change: 0.25p (5.88%)
Market closed Prices as at close on 11 October 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company. The Company is developing SNG001, an investigative formulation of inhaled interferon beta (IFN-B), for the treatment and prevention of various viral lung infections in high-risk patient groups. The Company has developed and is testing an inhaled formulation of IFN-B designed to directly target the lungs, the primary site of many viral lung infections, including COVID-19.

Contact details

Address:
Southampton General Hosp, Tremona Road
SOUTHAMPTON
SO16 6YD
United Kingdom
Telephone:
+44 (023) 80512800
Website:
https://www.synairgen.com/

Important dates

Future events
There are no future events available.
Past events
AGM 10 October 2024 10/10/24
Interim results 18 September 2024 18/09/24
Annual report 27 June 2024 27/06/24
Final results 27 June 2024 27/06/24

General stock information

EPIC:
SNG
ISIN:
GB00B0381Z20
Market cap:
£8.57 million
Shares in issue:
201.37 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Simon Shaw
    Non-Executive Chairman of the Board
  • Richard Marsden
    Chief Executive Officer, Executive Director
  • Joseph Colliver
    Chief Financial Officer, Executive Director
  • Richard Francis
    Senior Vice President, Head of CMC and Quality
  • Phillip Monk
    Chief Scientific Officer, Executive Director
  • Marcin Mankowski
    Chief Medical Officer
  • Simon Holden
    Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.